110 related articles for article (PubMed ID: 34135160)
1. Expression patterns and prognostic significances of
Khetan K; Sahoo RK; Baloda V; Shalimar ; Vishnubhatla S; Saraya A; Dash NR; Sharma A; DattaGupta S; Das P
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S160-S165. PubMed ID: 34135160
[TBL] [Abstract][Full Text] [Related]
2. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
4. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.
Zito Marino F; Baselice S; Erra S; Ronchi A; Montella M; Morgillo F; Vicidomini G; Santini M; Poziello G; Cozzolino I; Accardo M; Franco R
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):231-238. PubMed ID: 32842027
[TBL] [Abstract][Full Text] [Related]
5. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Valsecchi ME; Holdbrook T; Leiby BE; Pequignot E; Littman SJ; Yeo CJ; Brody JR; Witkiewicz AK
BMC Cancer; 2012 Mar; 12():104. PubMed ID: 22436573
[TBL] [Abstract][Full Text] [Related]
7. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
8. Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Kim M; Ku JH; Kwak C; Kim HH; Lee E; Keam B; Kim TM; Heo DS; Lee SH; Moon KC
PLoS One; 2015; 10(7):e0133371. PubMed ID: 26200905
[TBL] [Abstract][Full Text] [Related]
9. An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment.
Fisher SB; Patel SH; Bagci P; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Maithel SK
Cancer; 2013 Jan; 119(2):445-53. PubMed ID: 22569992
[TBL] [Abstract][Full Text] [Related]
10. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
Muñoz-Montaño W; Muñiz-Hernández S; Avilés-Salas A; Catalán R; Lara-Mejía L; Samtani-Bassarmal S; Cardona AF; Mendoza-Desión J; Hernández-Cueto D; Maldonado A; Baay-Guzmán G; Huerta-Yepes S; Arrieta O
BMC Cancer; 2021 Aug; 21(1):892. PubMed ID: 34353292
[TBL] [Abstract][Full Text] [Related]
11. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
Akita H; Zheng Z; Takeda Y; Kim C; Kittaka N; Kobayashi S; Marubashi S; Takemasa I; Nagano H; Dono K; Nakamori S; Monden M; Mori M; Doki Y; Bepler G
Oncogene; 2009 Aug; 28(32):2903-9. PubMed ID: 19543324
[TBL] [Abstract][Full Text] [Related]
12. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
13. Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer.
Wang X; Zhao J; Yang L; Mao L; An T; Bai H; Wang S; Liu X; Feng G; Wang J
Med Oncol; 2010 Jun; 27(2):484-90. PubMed ID: 19488864
[TBL] [Abstract][Full Text] [Related]
14. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Bellmunt J; Paz-Ares L; Cuello M; Cecere FL; Albiol S; Guillem V; Gallardo E; Carles J; Mendez P; de la Cruz JJ; Taron M; Rosell R; Baselga J;
Ann Oncol; 2007 Mar; 18(3):522-8. PubMed ID: 17229776
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
[TBL] [Abstract][Full Text] [Related]
16. The expression of ERCC1, RRM1, and BRCA1 in breast cancer according to the immunohistochemical phenotypes.
Kim D; Jung W; Koo JS
J Korean Med Sci; 2011 Mar; 26(3):352-9. PubMed ID: 21394302
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701).
Bepler G; Zinner RG; Moon J; Calhoun R; Kernstine K; Williams CC; Mack PC; Oliveira V; Zheng Z; Stella PJ; Redman MW; Gandara DR
Cancer; 2014 Aug; 120(15):2343-51. PubMed ID: 24752945
[TBL] [Abstract][Full Text] [Related]
18. Expression of ERCC1, RRM1, TUBB3 in correlation with apoptosis repressor ARC, DNA mismatch repair proteins and p53 in liver metastasis of colorectal cancer.
Tóth C; Sükösd F; Valicsek E; Herpel E; Schirmacher P; Renner M; Mader C; Tiszlavicz L; Kriegsmann J
Int J Mol Med; 2017 Nov; 40(5):1457-1465. PubMed ID: 28949378
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
20. Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.
Maus MK; Mack PC; Astrow SH; Stephens CL; Zeger GD; Grimminger PP; Hsiang JH; Huang E; Li T; Lara PN; Danenberg KD; Gandara DR
J Thorac Oncol; 2013 May; 8(5):582-6. PubMed ID: 23470290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
